1031 related articles for article (PubMed ID: 23273592)
1. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure.
Alehagen U; Dahlström U; Rehfeld JF; Goetze JP
J Card Fail; 2013 Jan; 19(1):31-9. PubMed ID: 23273592
[TBL] [Abstract][Full Text] [Related]
2. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
[TBL] [Abstract][Full Text] [Related]
3. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure.
Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T
J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002
[TBL] [Abstract][Full Text] [Related]
5. Adaptive cardiovascular hormones in a spectrum of heart failure phenotypes.
Zabarovskaja S; Hage C; Linde C; Daubert JC; Donal E; Gabrielsen A; Mellbin L; Lund LH
Int J Cardiol; 2015; 189():6-11. PubMed ID: 25885866
[TBL] [Abstract][Full Text] [Related]
6. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pleural N-terminal pro-B-type natriuretic peptide, midregion pro-atrial natriuretic peptide and mid-region pro-adrenomedullin for the diagnosis of pleural effusions associated with cardiac failure.
Porcel JM; Bielsa S; Morales-Rull JL; Civit C; Cao G; Light RW; Esquerda A
Respirology; 2013 Apr; 18(3):540-5. PubMed ID: 23278975
[TBL] [Abstract][Full Text] [Related]
8. Multiple biomarker strategy for improved diagnosis of acute heart failure in older patients presenting to the emergency department.
Bahrmann P; Bahrmann A; Hofner B; Christ M; Achenbach S; Sieber CC; Bertsch T
Eur Heart J Acute Cardiovasc Care; 2015 Apr; 4(2):137-47. PubMed ID: 25002708
[TBL] [Abstract][Full Text] [Related]
9. Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.
Kubler P; Jankowska EA; Majda J; Reczuch K; Banasiak W; Ponikowski P
Int J Cardiol; 2008 Oct; 129(3):373-8. PubMed ID: 18054808
[TBL] [Abstract][Full Text] [Related]
10. Mid-region pro-adrenomedullin adds predictive value to clinical predictors and Framingham risk score for long-term mortality in stable outpatients with heart failure.
Xue Y; Taub P; Iqbal N; Fard A; Clopton P; Maisel A
Eur J Heart Fail; 2013 Dec; 15(12):1343-9. PubMed ID: 23887059
[TBL] [Abstract][Full Text] [Related]
11. Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
Walter T; Brueckmann M; Lang S; Sauer T; Fiedler E; Papassotiriou J; Behnes M; Elmas E; Borggrefe M; Bertsch T
Clin Lab; 2010; 56(7-8):303-9. PubMed ID: 20857894
[TBL] [Abstract][Full Text] [Related]
12. Midregional proadrenomedullin (MR-proADM) in the risk stratification of patients with acute pulmonary embolism.
Pedowska-Włoszek J; Kostrubiec M; Kurnicka K; Ciurzynski M; Palczewski P; Pruszczyk P
Thromb Res; 2013 Nov; 132(5):506-10. PubMed ID: 24060192
[TBL] [Abstract][Full Text] [Related]
13. Direct comparison of mid-regional pro-atrial natriuretic peptide with N-terminal pro B-type natriuretic peptide in the diagnosis of patients with atrial fibrillation and dyspnoea.
Eckstein J; Potocki M; Murray K; Breidthardt T; Ziller R; Mosimann T; Klima T; Hoeller R; Moehring B; Sou SM; Rubini Gimenez M; Morgenthaler NG; Mueller C
Heart; 2012 Oct; 98(20):1518-22. PubMed ID: 22865868
[TBL] [Abstract][Full Text] [Related]
14. Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea.
Shah RV; Truong QA; Gaggin HK; Pfannkuche J; Hartmann O; Januzzi JL
Eur Heart J; 2012 Sep; 33(17):2197-205. PubMed ID: 22645194
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of midregional pro-adrenomedullin compared to natriuretic peptides for incident cardiovascular disease and heart failure in the population-based FINRISK 1997 cohort.
Funke-Kaiser A; Havulinna AS; Zeller T; Appelbaum S; Jousilahti P; Vartiainen E; Blankenberg S; Sydow K; Salomaa V
Ann Med; 2014 May; 46(3):155-62. PubMed ID: 24506434
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of plasma MR-proADM vs NT-proBNP for heart failure in people with type 2 diabetes: the SURDIAGENE prospective study.
Fraty M; Velho G; Gand E; Fumeron F; Ragot S; Sosner P; Mohammedi K; Gellen B; Saulnier PJ; Halimi JM; Montaigne D; Ducrocq G; Rehman M; Marre M; Roussel R; Hadjadj S;
Diabetologia; 2018 Dec; 61(12):2643-2653. PubMed ID: 30232509
[TBL] [Abstract][Full Text] [Related]
17. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.
Michtalik HJ; Yeh HC; Campbell CY; Haq N; Park H; Clarke W; Brotman DJ
Am J Cardiol; 2011 Apr; 107(8):1191-5. PubMed ID: 21296322
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Mortality in Chest Pain Patients: Comparison of Natriuretic Peptides With Novel Biomarkers of Cardiovascular Stress.
Sinning C; Ojeda F; Zeller T; Zengin E; Rupprecht HJ; Lackner KJ; Bickel C; Blankenberg S; Schnabel RB; Westermann D
Can J Cardiol; 2016 Dec; 32(12):1470-1477. PubMed ID: 27568502
[TBL] [Abstract][Full Text] [Related]
19. Risk of cardiovascular death in elderly patients with possible heart failure. B-type natriuretic peptide (BNP) and the aminoterminal fragment of ProBNP (N-terminal proBNP) as prognostic indicators in a 6-year follow-up of a primary care population.
Alehagen U; Lindstedt G; Levin LA; Dahlström U
Int J Cardiol; 2005 Apr; 100(1):125-33. PubMed ID: 15820295
[TBL] [Abstract][Full Text] [Related]
20. Heart failure mortality according to acute variations in N-terminal pro B-type natriuretic peptide and cystatin C levels.
Carrasco-Sánchez FJ; Pérez-Calvo JI; Morales-Rull JL; Galisteo-Almeda L; Páez-Rubio I; Barón-Franco B; Aguayo-Canela M; Pujol-De la llave E
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):115-21. PubMed ID: 24522084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
